|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM161B |
Gene summary for TMEM161B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM161B | Gene ID | 153396 |
| Gene name | transmembrane protein 161B | |
| Gene Alias | FLB3342 | |
| Cytomap | 5q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | B7Z6T3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 153396 | TMEM161B | HTA11_3410_2000001011 | Human | Colorectum | AD | 9.18e-12 | -4.80e-01 | 0.0155 |
| 153396 | TMEM161B | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.49e-04 | -4.43e-01 | -0.1808 |
| 153396 | TMEM161B | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.34e-06 | -5.15e-01 | -0.1207 |
| 153396 | TMEM161B | HTA11_696_2000001011 | Human | Colorectum | AD | 3.02e-09 | -4.26e-01 | -0.1464 |
| 153396 | TMEM161B | HTA11_866_2000001011 | Human | Colorectum | AD | 1.72e-08 | -4.18e-01 | -0.1001 |
| 153396 | TMEM161B | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.70e-07 | -4.50e-01 | -0.059 |
| 153396 | TMEM161B | HTA11_866_3004761011 | Human | Colorectum | AD | 7.36e-08 | -4.52e-01 | 0.096 |
| 153396 | TMEM161B | HTA11_10711_2000001011 | Human | Colorectum | AD | 7.00e-05 | -4.66e-01 | 0.0338 |
| 153396 | TMEM161B | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.25e-08 | -4.07e-01 | 0.0674 |
| 153396 | TMEM161B | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.12e-06 | -3.85e-01 | 0.294 |
| 153396 | TMEM161B | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.04e-09 | -3.95e-01 | 0.3859 |
| 153396 | TMEM161B | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.49e-18 | -4.87e-01 | 0.3005 |
| 153396 | TMEM161B | A001-C-207 | Human | Colorectum | FAP | 5.59e-03 | -3.07e-01 | 0.1278 |
| 153396 | TMEM161B | A015-C-203 | Human | Colorectum | FAP | 7.17e-19 | -4.22e-01 | -0.1294 |
| 153396 | TMEM161B | A015-C-204 | Human | Colorectum | FAP | 2.84e-06 | -3.50e-01 | -0.0228 |
| 153396 | TMEM161B | A014-C-040 | Human | Colorectum | FAP | 2.17e-02 | -4.01e-01 | -0.1184 |
| 153396 | TMEM161B | A002-C-201 | Human | Colorectum | FAP | 7.00e-07 | -2.07e-01 | 0.0324 |
| 153396 | TMEM161B | A002-C-203 | Human | Colorectum | FAP | 9.91e-06 | -2.57e-01 | 0.2786 |
| 153396 | TMEM161B | A001-C-119 | Human | Colorectum | FAP | 5.46e-08 | -4.21e-01 | -0.1557 |
| 153396 | TMEM161B | A001-C-108 | Human | Colorectum | FAP | 5.65e-12 | -3.29e-01 | -0.0272 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM161B | SNV | Missense_Mutation | novel | c.977G>T | p.Arg326Leu | p.R326L | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-A7-A3RF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
| TMEM161B | SNV | Missense_Mutation | novel | c.1172T>C | p.Leu391Pro | p.L391P | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TMEM161B | SNV | Missense_Mutation | novel | c.256N>A | p.Glu86Lys | p.E86K | protein_coding | deleterious(0.01) | benign(0.272) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| TMEM161B | SNV | Missense_Mutation | novel | c.794N>A | p.Ile265Asn | p.I265N | protein_coding | tolerated(0.06) | possibly_damaging(0.596) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMEM161B | SNV | Missense_Mutation | novel | c.829C>T | p.Pro277Ser | p.P277S | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-CM-6168-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM161B | SNV | Missense_Mutation | c.801N>T | p.Gln267His | p.Q267H | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-D5-7000-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TMEM161B | SNV | Missense_Mutation | c.229N>G | p.Ile77Val | p.I77V | protein_coding | tolerated(1) | benign(0.005) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| TMEM161B | SNV | Missense_Mutation | c.488A>G | p.Glu163Gly | p.E163G | protein_coding | deleterious(0.01) | possibly_damaging(0.473) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TMEM161B | SNV | Missense_Mutation | novel | c.454C>A | p.Leu152Ile | p.L152I | protein_coding | deleterious(0.02) | possibly_damaging(0.889) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TMEM161B | insertion | Frame_Shift_Ins | novel | c.728_729insT | p.Leu243PhefsTer90 | p.L243Ffs*90 | protein_coding | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |